| $385M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $363,843 | 26 | 100 |
| Abate Kristin | Chief Accounting Officer | 0 | $0 | 7 | $5,895 | $-5,895 |
| Macomber Lori | EVP, CFO & Treasurer | 0 | $0 | 1 | $10,244 | $-10,244 |
| Mano Michael | SVP, General Counsel&Secretary | 0 | $0 | 3 | $37,210 | $-37,210 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 0 | $0 | 3 | $48,489 | $-48,489 |
| Rangwala Reshma | EVP & Chief Medical Officer | 0 | $0 | 4 | $58,182 | $-58,182 |
| Poulton Stuart | EVP, Chief Development Officer | 0 | $0 | 5 | $58,502 | $-58,502 |
| Paulson Richard A. | President and CEO | 0 | $0 | 3 | $145,322 | $-145,322 |
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Over the last 12 months, insiders at Karyopharm Therapeutics Inc. have bought $0 and sold $363,843 worth of Karyopharm Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Karyopharm Therapeutics Inc. have bought $49,985 and sold $804,414 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 41,140 shares for transaction amount of $49,985 was made by BOHLIN GAREN G (director) on 2023‑09‑12.
| 2026-05-14 | Sale | Paulson Richard A. | President and CEO | 2,203 0.0275% | $9.50 | $20,929 | -0.65% | |
| 2026-05-14 | Sale | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 324 0.0041% | $9.50 | $3,078 | -0.65% | |
| 2026-05-14 | Sale | Poulton Stuart | EVP, Chief Development Officer | 403 0.005% | $9.50 | $3,829 | -0.65% | |
| 2026-05-14 | Sale | Mano Michael | EVP, CLO&Secretary | 266 0.0033% | $9.50 | $2,527 | -0.65% | |
| 2026-05-14 | Sale | Rangwala Reshma | EVP & Chief Medical Officer | 408 0.0051% | $9.50 | $3,876 | -0.65% | |
| 2026-05-14 | Sale | Abate Kristin | Chief Accounting Officer | 53 0.0007% | $9.50 | $504 | -0.65% | |
| 2026-04-21 | Sale | Rangwala Reshma | EVP & Chief Medical Officer | 449 0.0051% | $8.94 | $4,014 | -3.93% | |
| 2026-03-02 | Sale | Paulson Richard A. | President and CEO | 12,361 0.1448% | $9.41 | $116,311 | -10.79% | |
| 2026-03-02 | Sale | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 4,604 0.0539% | $9.41 | $43,321 | -10.79% | |
| 2026-03-02 | Sale | Poulton Stuart | EVP, Chief Development Officer | 5,101 0.0597% | $9.41 | $47,998 | -10.79% | |
| 2026-03-02 | Sale | Mano Michael | EVP, CLO&Secretary | 3,526 0.0413% | $9.41 | $33,178 | -10.79% | |
| 2026-03-02 | Sale | Rangwala Reshma | EVP & Chief Medical Officer | 5,066 0.0593% | $9.41 | $47,669 | -10.79% | |
| 2026-02-17 | Sale | Poulton Stuart | EVP, Chief Development Officer | 378 0.0041% | $8.63 | $3,262 | -7.87% | |
| 2026-02-03 | Sale | Macomber Lori | EVP, CFO & Treasurer | 1,626 0.0183% | $6.30 | $10,244 | +31.37% | |
| 2026-01-28 | Sale | Abate Kristin | Chief Accounting Officer | 50 0.0006% | $7.03 | $352 | +23.84% | |
| 2026-01-21 | Sale | Abate Kristin | Chief Accounting Officer | 265 0.0029% | $5.96 | $1,579 | +34.89% | |
| 2025-10-01 | Sale | Abate Kristin | Chief Accounting Officer | 362 0.004% | $6.30 | $2,279 | +15.78% | |
| 2025-09-15 | Sale | Paulson Richard A. | President and CEO | 1,257 0.0149% | $6.43 | $8,083 | +10.86% | |
| 2025-09-15 | Sale | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 325 0.0038% | $6.43 | $2,090 | +10.86% | |
| 2025-09-15 | Sale | Rangwala Reshma | EVP & Chief Medical Officer | 408 0.0048% | $6.43 | $2,623 | +10.86% |
| Paulson Richard A. | President and CEO | 269747 1.1903% | $2.29M | 0 | 42 | |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 107940 0.4763% | $917,490.00 | 0 | 10 | |
| Poulton Stuart | EVP, Chief Development Officer | 94821 0.4184% | $805,978.50 | 0 | 12 | |
| Mano Michael | EVP, CLO&Secretary | 94398 0.4165% | $802,383.00 | 0 | 9 | |
| Macomber Lori | EVP, CFO & Treasurer | 85105 0.3755% | $723,392.50 | 0 | 1 | |
| Rangwala Reshma | EVP & Chief Medical Officer | 56829 0.2508% | $483,046.50 | 0 | 9 | |
| Abate Kristin | Chief Accounting Officer | 23801 0.105% | $202,308.50 | 0 | 7 | |
| Chione Ltd | 10 percent owner | 6000000 26.4749% | $51M | 0 | 60 | |
| Plio Ltd | 10 percent owner | 3143473 13.8705% | $26.72M | 0 | 1 | |
| Czernik Marcin | 10 percent owner | 2850517 12.5779% | $24.23M | 0 | 14 | |
| Kauffman Michael | director | 713757 3.1494% | $6.07M | 0 | 64 | |
| Shacham Sharon | Chief Scientific Officer | 713757 3.1494% | $6.07M | 0 | 64 | |
| Mason Michael | EVP, CFO & Treasurer | 391054 1.7255% | $3.32M | 0 | 15 | |
| Frenkel Ran | EVP, Chief Dev. Officer | 168290 0.7426% | $1.43M | 2 | 9 | <0.0001% |
| Shah Jatin | EVP, Chief Medical Officer | 129450 0.5712% | $1.1M | 1 | 6 | <0.0001% |
| Mitchener Stephen | SVP, Chief Business Officer | 128313 0.5662% | $1.09M | 0 | 3 | |
| Brannelly Paul | SVP, FINANCE & ADMIN, TREAS | 66136 0.2918% | $562,156.00 | 3 | 0 | +28.27% |
| BOHLIN GAREN G | director | 45140 0.1992% | $383,690.00 | 2 | 0 | <0.0001% |
| Renz Justin A | EVP, CFO & Treasurer | 19173 0.0846% | $162,970.50 | 1 | 1 | <0.0001% |
| DEMAREE JOHN | Chief Commercial Officer | 7500 0.0331% | $63,750.00 | 1 | 0 | <0.0001% |
| Primiano Christopher Brett | EVP, CBO, GC & Secretary | 4523 0.02% | $38,445.50 | 1 | 23 | +28.32% |
| Lewis Tanya | EVP, Chief Reg. Affairs | 4143 0.0183% | $35,215.50 | 0 | 2 | |
| Greene Barry E | director | 3000 0.0132% | $25,500.00 | 1 | 0 | <0.0001% |
| PAKIANATHAN DEEPIKA | director | 0 0% | $0 | 5 | 7 | +36.69% |
| Mirza Mansoor Raza | director | 0 0% | $0 | 0 | 24 |
$16,153,236 | 20 | -28.79% | $172.18M | |
Karyopharm Therapeutics Inc. (KPTI) | $20,234,041 | 17 | 2.09% | $192.64M |
$156,530,514 | 13 | 45.71% | $211.26M | |
$1,037,470 | 13 | 78.00% | $202.37M | |
$15,799,576 | 12 | -39.52% | $214.62M | |
$19,167,169 | 10 | 28.48% | $186.14M | |
$119,804,612 | 8 | -17.22% | $186.82M | |
$145,296,407 | 8 | -0.98% | $203.62M | |
$2,762,881 | 8 | -10.76% | $213.89M | |
$603,645 | 8 | 57.40% | $217.59M | |
$344,394 | 8 | -22.26% | $182.49M | |
$32,007,657 | 4 | -45.65% | $183.53M | |
$193,101 | 3 | -25.20% | $209.69M | |
$32,289,200 | 3 | -5.46% | $182.08M | |
$16,003,671 | 3 | 55.38% | $173.82M | |
$15,551,156 | 3 | 98.82% | $210.7M | |
$12,498 | 2 | 39.61% | $181.26M | |
$86,200 | 1 | -19.57% | $186.67M | |
$63,731 | 1 | -19.50% | $212.76M |
| Increased Positions | 46 | +92% | 7M | +221.08% |
| Decreased Positions | 16 | -32% | 115,963 | -3.89% |
| New Positions | 27 | New | 5M | New |
| Sold Out Positions | 11 | Sold Out | 91,181 | Sold Out |
| Total Postitions | 80 | +60% | 9M | +217.2% |
| T. Rowe Price Investment Management, Inc. | $5,040.00 | 4.12% | 700,992 | -27,774 | -3.81% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $3,029.00 | 2.48% | 421,322 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,935.00 | 2.4% | 408,222 | -110,047 | -21.23% | 2025-09-30 |
| Blackrock, Inc. | $1,668.00 | 1.36% | 231,951 | -4,690 | -1.98% | 2025-09-30 |
| Catalio Capital Management, Lp | $1,028.00 | 0.84% | 142,984 | -3,029 | -2.07% | 2025-09-30 |
| Avidity Partners Management Lp | $968.00 | 0.79% | 134,566 | 0 | 0% | 2025-09-30 |
| Marshall Wace, Llp | $924.00 | 0.76% | 128,451 | 0 | 0% | 2025-09-30 |
| C Worldwide Group Holding A/S | $719.00 | 0.59% | 100,000 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $671.00 | 0.55% | 93,289 | +1,448 | +1.58% | 2025-09-30 |
| Group One Trading Llc | $492.00 | 0.4% | 68,436 | -29,464 | -30.1% | 2025-09-30 |